Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Rapid Micro Biosystems (RPID) over the last 6 years, with Q3 2025 value amounting to $599000.0.

  • Rapid Micro Biosystems' Change in Accured Expenses rose 16924.86% to $599000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.5 million, marking a year-over-year decrease of 17171.17%. This contributed to the annual value of -$3.9 million for FY2024, which is 37126.92% down from last year.
  • According to the latest figures from Q3 2025, Rapid Micro Biosystems' Change in Accured Expenses is $599000.0, which was up 16924.86% from $335000.0 recorded in Q2 2025.
  • Rapid Micro Biosystems' 5-year Change in Accured Expenses high stood at $2.9 million for Q4 2023, and its period low was -$3.9 million during Q1 2022.
  • Over the past 5 years, Rapid Micro Biosystems' median Change in Accured Expenses value was -$341000.0 (recorded in 2021), while the average stood at -$209473.7.
  • As far as peak fluctuations go, Rapid Micro Biosystems' Change in Accured Expenses crashed by 39679.9% in 2022, and later skyrocketed by 2886000.0% in 2023.
  • Rapid Micro Biosystems' Change in Accured Expenses (Quarter) stood at -$341000.0 in 2021, then soared by 102.93% to $10000.0 in 2022, then skyrocketed by 28860.0% to $2.9 million in 2023, then plummeted by 115.16% to -$439000.0 in 2024, then surged by 236.45% to $599000.0 in 2025.
  • Its Change in Accured Expenses was $599000.0 in Q3 2025, compared to $335000.0 in Q2 2025 and -$2.0 million in Q1 2025.